B E Heckman studies the effects of vaccines on children, specifically in the context of those living with HIV. They researched the safety and effectiveness of the quadrivalent meningococcal conjugate vaccine, which protects against four different types of bacteria that can cause serious infections. Their work helps ensure that children with HIV can receive necessary vaccines while identifying the need for more frequent booster shots to maintain protection against certain disease types.
Key findings
The quadrivalent meningococcal conjugate vaccine was found to be safe for HIV-infected children, with only mild side effects reported.
Most children developed protective immunity after receiving the vaccine, but protection against serogroups A and C significantly dropped after one year.
The study indicates that HIV-infected children may require booster shots more often than their healthy peers to sustain adequate immunity.
Frequently asked questions
Does Dr. Heckman study vaccines for children?
Yes, Dr. Heckman focuses on vaccine safety and effectiveness for children, especially those who are HIV-infected.
What vaccines has Dr. Heckman researched?
Dr. Heckman has researched the quadrivalent meningococcal conjugate vaccine, which protects against four strains of meningococcal disease.
Is Dr. Heckman's work relevant to HIV-infected children?
Yes, their research specifically examines how HIV-infected children respond to vaccines and the implications for their immunization schedules.
Publications in plain English
Protecting households on exposure to newly diagnosed index multidrug-resistant tuberculosis patients: Study protocol for the PHOENIx phase 3 clinical trial.
2025
Contemporary clinical trials
Kendall MA, Hughes MD, Kim S, Aaron LA, Naini L +14 more
Plain English The study evaluates whether a new drug called delamanid can effectively prevent active tuberculosis in high-risk household contacts of patients with multidrug-resistant tuberculosis (MDR-TB). Specifically, the trial is comparing delamanid to the standard treatment, isoniazid, over a period of 96 weeks, aiming to reduce the number of household contacts who develop TB from 5% to 2.5%. This research is important because as fluoroquinolone-resistant TB cases rise, finding effective treatment options is crucial to protect vulnerable populations.
Who this helps: This helps patients and their families who are at risk of developing tuberculosis.
Assessment of lopinavir pharmacokinetics with respect to developmental changes in infants and the impact on weight band-based dosing.
2012
Clinical pharmacology and therapeutics
Nikanjam M, Chadwick EG, Robbins B, Alvero C, Palumbo P +7 more
Plain English This study looked at how the drug lopinavir works in the bodies of very young infants with HIV to determine the best way to dose it as they grow. Researchers found that younger infants cleared the drug from their system more quickly, and as they aged, this clearance slowed down. The recommended dosing based on weight from the World Health Organization effectively achieved the desired drug levels in infants, in line with other suggested dosing methods.
Who this helps: This helps doctors treating HIV-infected infants by providing guidance on how to dose medications effectively.
Safety and immunogenicity of quadrivalent meningococcal conjugate vaccine in 2- to 10-year-old human immunodeficiency virus-infected children.
2012
The Pediatric infectious disease journal
Siberry GK, Warshaw MG, Williams PL, Spector SA, Decker MD +8 more
Plain English Researchers tested whether a meningococcal vaccine was safe and effective in HIV-infected children ages 2-10, giving some children two doses and tracking their immune response over time. The vaccine was safe with only mild side effects, and most children developed protective immunity after vaccination—though protection against two of the four disease types (serogroups A and C) faded significantly within a year. These results show that HIV-infected children can safely receive this vaccine and benefit from it, but they may need booster shots more frequently than other children to maintain protection against all disease types.
Long-term outcomes for HIV-infected infants less than 6 months of age at initiation of lopinavir/ritonavir combination antiretroviral therapy.
2011
AIDS (London, England)
Chadwick EG, Yogev R, Alvero CG, Hughes MD, Hazra R +6 more
Plain English This study looked at how effective and safe a specific HIV treatment, lopinavir/ritonavir (LPV/r), is for infants under 6 months old. Researchers followed 31 HIV-infected infants and found that after 48 weeks, 71% had low levels of the virus in their blood, and 66% maintained this low level for the entire study period. These findings are important because they show that young infants can respond well to this treatment, but it's crucial to adjust doses as they grow.
Who this helps: This helps infants living with HIV and their healthcare providers.
Phase I/II, open-label trial of safety and immunogenicity of meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine in human immunodeficiency virus-infected adolescents.
2010
The Pediatric infectious disease journal
Siberry GK, Williams PL, Lujan-Zilbermann J, Warshaw MG, Spector SA +8 more
Plain English This study looked at the safety and effectiveness of a meningococcal vaccine in young people aged 11 to 24 who are infected with HIV. Out of 319 participants, only 3.1% had mild and temporary side effects, while 52% showed a good immune response to at least one type of meningococcal bacteria after getting the vaccine. This matters because it shows that while the vaccine is safe for HIV-infected youth, they may not respond as well as healthy peers, especially those with more serious health conditions.
Who this helps: This helps HIV-infected adolescents and their healthcare providers.
Abacavir pharmacokinetics during chronic therapy in HIV-1-infected adolescents and young adults.
2009
Clinical pharmacology and therapeutics
Sleasman JW, Robbins BL, Cross SJ, Lindsey JC, Kraimer JM +9 more
Plain English This study examined how the medication abacavir is processed in the bodies of 30 adolescents and young adults aged 13 to 25 who are living with HIV. Researchers found that the drug's effects were similar in younger patients (under 18) and older ones (18 and over), meaning that the recommended adult dosage of 300 mg twice daily is appropriate for both groups. This is important because it confirms that adolescents and young adults can safely use the same dosage as adults without needing adjustments.
Who this helps: This helps HIV-infected adolescents and young adults by ensuring they receive the correct medication dose.
Plain English This study looked at giving a HIV treatment called lopinavir/ritonavir to infants less than 6 weeks old. Researchers found that 8 out of 10 infants managed to control the virus after 24 weeks, even though some babies had lower drug levels than older infants. This is important because it shows that starting treatment early can help young HIV-infected infants stay healthier.
Who this helps: This helps infants diagnosed with HIV and their caregivers.